Astria Therapeutics Inc. has released a corporate presentation detailing its ongoing efforts in developing treatments for hereditary angioedema $(HAE)$ and atopic dermatitis. The presentation highlights Astria's progress with navenibart, a half-life extended monoclonal antibody inhibitor of plasma kallikrein, which is currently undergoing the ALPHA-ORBIT Phase 3 trial. This trial aims to support the registration of Q3M and Q6M navenibart administration as a potential market-leading treatment for HAE. The presentation also outlines Astria's pipeline milestones, including initial results from the ALPHA-SOLAR study anticipated in Q2 2025. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.